Abstract：Stereotactic body radiation therapy (SBRT) refers to the use of stereotactic isocentric rotation technology, which concent rates high-energy radiation in the target area for a large dose of irradiation, causing irreversible biological damage, while the normal tissue is not or less exposed. Currently, SBRT is the standard treatment for inoperable patients with early non-small cell lung cancer (NSCLC). The efficacy of SBRT in the treatment of peripheral and central lung cancer has been validated, whereas there is no consensus on the dose and fractionation, which remains to be further explored. The clinical efficacy of SBRT combined with immunotherapy needs to be further studied. Therefore, the optimal dose and fractionation of SBRT for early peripheral and central NSCLC were discussed, the difference in the clinical efficacy among SBRT, lobectomy and thoracoscopic surgery was analyzed and the clinical efficacy of SBRT combined with immunotherapy was assessed, aiming to provide theoretical basis for the application of SBRT in clinical practice.
Yu Hongfang,Yu Zhilong. Research progress on stereotactic radiation therapy for early non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(6): 482-485.
[1] Wang SW, Wang XX, Zhou Q, et al. Stereotactic ablative radiotherapy versus lobectomy for stage Ⅰ non-small cell lung cancer:A systematic review[J]. Thorac Cancer, 2018, 9(3):337–347. DOI:10.1111/1759-7714.12574. [2] Coros CD, Park HS, Moreno AC, et al. Stage Ⅰ lung cancer SBRT clinical practice patterns[J]. Clin Oncol, 2017, 40(4):358-361. DOI:10.1097/COC.0000000000000162. [3] Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015, 16(6):630-637. DOI:10.1016/S1470-2045(15)70168-3. [4] Eriguchi T, Takeda A, Sanuki N, et al. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer[J]. Lung Cancer, 2017, 109:62–67. DOI:10.1016/j.lungcan.2017.04.22. [5] Tsurugai Y, Takeda A, Sanuki N, et al. Stereotactic body radiotherapy for patients with non-small-cell lung cancer using RapidArc delivery and a steep dose gradient:prescription of 60% isodose line of maximum dose fitting to the planning target volume[J]. J Radiat Res, 2019, 60(3):364-370. DOI:10.1093/jrr/rry112. [6] Stam B, Grills IS, Kwint M, et al. SBRT for central tumors in early stage NSCLC patients[J]. Int J Radiat Oncol Biol Phys, 2017, 99(2):S17. DOI:10.1016/j.ijrobp.2017.06.054. [7] Onimaru R, Shirato H, Shibata T, et al. Phase Ⅰ study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV<100cc using a continual reassessment method (JCOG0702)[J]. Radiother Oncol, 2015, 116(2):276-280. DOI:10.1016/j.radonc. 2015.07.008. [8] Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1-2N0M0 non-small cell lung cancer:japan clinical oncology group study JCOG0403[J]. Int J Radiat Oncol Biol Phys, 2015, 93(5):989–996. DOI:10.1016/j.ijrobp.2015.07.2278. [9] Kimura T, Nagata Y, Harada H, et al. Phase Ⅰ study of stereotactic body radiation therapy for centrally located stage Ⅰ A non-small cell lung cancer (JROSG10-1)[J]. Clin Oncol, 2017, 22(5):849-856. DOI:10.1007/s10147-017-1125-y. [10] 董林,秦庆亮,李钦传. 立体定向放射治疗早期非小细胞肺癌:进展与挑战[J] 肿瘤, 2018, 38(3):264-269. DOI:10.3781/j.issn.1000-7431.2018.55.700. Dong L, Qin QL, Li QC. Stereotactic ablation radiotherapy for early stage non-small cell lung cancer: progress and challenge[J]. Tumor, 2018, 38(3): 264-269. DOI:10.3781/j.issn.1000-7431.2018.55.700. [11] Haasbeek CJ, Lagerwaard FJ, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer[J]. J Thorac Oncol, 2011, 6(12):2036-2043. DOI:10.1097/JTO.0b013e31822e71d8. [12] Bezjak, A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer:NRG Oncology/RTOG 0813 Trial[J]. J Clin Oncol, 2019, 37(15):1316-1325. DOI:10.1200/JCO.18.00622. [13] Hamaji M, Chen F, Matsuo Y, et al. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage Ⅰ lung cancer[J]. Ann Thorac Surg, 2015, 99(4):1122–1129. DOI:10.1016/j.athoracsur.2014.11.009. [14] Cornwell LD, Echeverria AE, Samuelian J, et al. Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage Ⅰ lung cancer[J]. J Thorac Cardiovasc Surg, 2018, 155(1):395–402. DOI:10.1016/j.jtcvs.2017.07.065. [15] 李放,葛宏雷,金昊. 电视辅助胸腔镜手术和体部立体定向放疗治疗早期非小细胞肺癌的临床疗效比较[J]. 临床和实验医学杂志, 2017, 16(10):1008-1010. DOI:10.3969/j.issn.1671-4695.2017.10.023. Li Fang, Ge Honglei, Jin Hao. Comparison of clinical efficacy of video-assisted thoracoscopic surgery and body stereotactic radiotherapy in the treatment of early non-small cell lung cancer [J]. J clin exper med, 2017, 16 (10): 1008-1010. DOI: 10.3969/j.issn.1671-4695.2017.10.023. [16] Ma LF, Xiang JQ. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: a meta-analysis[J]. Thorac Cancer, 2016, 7(4):442-451. DOI:10.1111/1759-7714.12352. [17] Brooks ED, Sun B, Feng L, et al. Association of long-term outcomes and survival with multidisciplinary salvage treatment for local and regional recurrence after stereotactic ablative radiotherapy for early-stage lung cancer[J]. JAMA Netw Open, 2018, 1(4):e181390. DOI:10.1001/jamanetworkopen.2018.1390. [18] Dong BQ, Wang J, Xu YJ, et al. Comparision of the efficacy of stereotactic body radiotherapy versus surgical treatment for early-stage non-small cell lung cancer after propensity score matching[J]. Transl Oncol, 2019, 12(8):1032-1037. DOI:10.1016/j.tranon.2019.04.015. [19] Mokhles S, Verstegen N, Maat AP, et al. Comparison of clinical outcome of stage Ⅰ non-small cell lung cancer treated surgically or with stereotactic radiotherapy:Results from propensity score analysis[J]. Lung Cancer, 2015, 87(3):283-289. DOI:10.1016/j.lungcan.2015.01.005. [20] Zheng X, Schipper M, Kidwell K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage Ⅰ non-small cell lung cancer:a meta-analysis[J]. Int J Radiat Oncol Biol Phys, 2014, 90(3):603-611. DOI:10.1016/j.ijrobp.2014.05.055 [21] Chen H, Laba JM, Boldt RG, et al. Stereotactic ablative radiation therapy versus surgery in early lung cancer:a meta-analysis of propensity score studies[J]. Int J Radiat Oncol Biol Phys, 2018, 101(1):186-194. DOI:10.1016/j.ijrobp.2018.01.064. [22] Scotti V, Bruni A, Francolini G, et al. Stereotactic ablative radiotherapy as an alternative to lobectomy in patients with medically operable stage Ⅰ NSCLC:a retrospective, multicenter analysis[J]. Clin Lung Cancer, 2019, 20(1):e53-e61. DOI:10.1016/j.cllc.2018.09.003. [23] Stokes WA, Bronsert MR, Meguid RA, et al. Post-treatment mortality after surgery and stereotactic body radiotherapy for early-stage non-small-cell lung cancer[J]. J Clin Oncol, 2018, 36(7):642-651. DOI:10.1200/JCO.2017.75.6536. [24] Engelhard KE, Odell DD, DeCamp MM, et al. Comparing apples to oranges:short-term mortality after surgery versus stereotactic body radiotherapy for early stage non-small cell lung cancer[J]. J Thorac Dis, 2018, 10(17):S1974-S1976. DOI:10.21037/jtd.2018.04.66. [25] Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs. pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer:results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019, 5(9):1276-1282. DOI:10.1001/jamaoncol.2019.1478. [26] Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors[J]. Semin Radiat Oncol, 2015, 25(1):28-33. DOI:10.1016/j.semradonc.2014.07.004 [27] Zhang T, Yu H, Ni C, et al. Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage Ⅰ non-small-cell lung cancer[J]. Sci Rep, 2017, 7(1):4866. DOI:10.1038/s41598-017-04978-x. [28] Marciscano AE, Ghasemzadeh A, Nirschl T, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy[J]. Clin Cancer Res, 2018, 24(20):5058-5071. DOI:10.1158/1078-0432. CCR-17-3427. [29] Vansteenkiste J, Wauters E, Reymen B, et al. Current status of immune checkpoint inhibition in early-stage NSCLC[J]. Ann Oncol, 2019, 30(8):1244-1253. DOI:10.1093/annonc/mdz175.
2020, Vol. 29 
